Investigating Hybrid PLGA-Lipid Nanoparticles as an Innovative Delivery Tool for Palmitoylethanolamide to Muscle Cells
Laboratory studyOther animals
- Design
- Laboratory study
- Subjects
- C2C12 mouse myoblast cell culture
- Dose used in the study
- PEA-loaded hybrid PLGA-lipid nanoparticles, particle size about 150 nm
- Duration
- Not stated in the abstract
- What was measured
- Nanoparticle size, morphology, encapsulation efficiency and drug loading; drug release; cell viability and cytocompatibility; cellular uptake by confocal microscopy and flow cytometry.
What the authors reported
The hybrid nanoparticles had a mean size of about 150 nm, 79% encapsulation efficiency and drug loading of 44.2 mg/g, with enhanced drug release from amorphised PEA. They showed no toxicity, improved cell viability compared with unloaded particles, and were taken up efficiently and in a time-dependent way by muscle cells.
Limits of this study
A cell culture and formulation study; it cannot show effect in muscle in a living animal or person. The authors declare no conflicts of interest.
Source
PubMed 41304749 · doi:10.3390/pharmaceutics17111412
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.